Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
CD133 CRISPR Activation Plasmid (h): sc-418263-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CD133 CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- CD133 CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by CD133 CRISPR Activation Plasmid (h) and CD133 CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the PROM1 transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: CD133 Antibody (E-11): sc-365537
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD133 CRISPR Activation Plasmid (h) | sc-418263-ACT | 20 µg | $397.00 | |||
CD133 CRISPR Activation Plasmid (h2) | sc-418263-ACT-2 | 20 µg | $397.00 |
PROM1 encodes CD133, a pentaspan transmembrane glycoprotein enriched on plasma membrane protrusions where it contributes to membrane organization, vesicle trafficking, and maintenance of cell polarity. CD133 expression is frequently used to stratify stem-like subpopulations and is linked to programs controlling self-renewal, differentiation, and metabolic adaptation in epithelial and neural lineages. In cancer biology, PROM1/CD133 is widely studied as a marker associated with tumor heterogeneity, therapy resistance phenotypes, and metastatic potential, providing a tractable node for probing regulatory networks. Its expression dynamics also intersect with pathways governing cytoskeletal remodeling and microenvironmental signaling, making it relevant for studies of development and disease-associated cell state transitions.
CD133 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous PROM1 expression without altering the underlying DNA sequence.
CD133 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the PROM1 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the PROM1 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous CD133 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native PROM1 locus and enabling the study of CD133-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of CD133 pathway restoration in tumor cells with silenced or reduced PROM1 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.